2,038
Participants
Start Date
December 31, 2005
Primary Completion Date
January 31, 2007
Study Completion Date
January 31, 2007
Dexlansoprazole MR
Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
Dexlansoprazole MR
Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
Lansoprazole
Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Alabaster
Birmingham
Huntsville
Phoenix
Scottsdale
Tucson
Anaheim
Chula Vista
Fullerton
Garden Grove
Irvine
Lancaster
Long Beach
Los Angeles
Mission Hills
Palm Springs
Pasadena
Redwood City
San Diego
San Luis Obispo
Boulder
Colorado Springs
Lone Tree
Wheat Ridge
Waterbury
Boynton Beach
Jacksonsville
Jupiter
Kissimmee
Lakeland
New Port Richey
Atlanta
Honolulu
Arlington Heights
Chicago
Hines
Oak Park
Rockford
Clive
Dubuque
Newton
Shawnee Mission
Topeka
Metairie
Shreveport
Hollywood
Lutherville
Troy
Chaska
Jackson
Mexico
St Louis
Washington
Omaha
Pahrump
Binghamton
Brooklyn
Great Neck
Rochester
Charlotte
Elkin
Greensboro
Hickory
Salisbury
Statesville
Winston-Salem
Beachwood
Cincinnati
Mayfield Heights
Warren
Oklahoma City
Portland
Beaver Falls
Duncansville
Lansdale
Bristol
Chattanooga
Hermitage
Nashville
Austin
Beaumont
Byran
Corsicana
El Paso
Fort Worth
Houston
San Antonio
Bountiful
Ogden
Salt Lake City
West Jordan
Chesapeake
Danville
Spokane
Milwaukee
Monroe
Box Hill
South Brisbane
Sofia
Edmonton
Winnipeg
St. John's
Québec
Regina
Saskatoon
Prague
Hamburg
Dietzenback
Schweim
Borna
Gyula
Gujarat
Tamilnadu
Rajasthan
Ludhiana
Madurai
Chennai
Coimbatore
Hyderabad
New Delhi
Visakhapatnam
Riga
Kaunas
Hamilton
Lima
Krakow
Lubin
Sopot
Warzawa
Bratislava
Nitra
Sučany
Tmava
Gauteng
Cape Town
Panorama
Pinelands
Plumstead
Somerset West
Pretoria
Lead Sponsor
Takeda
INDUSTRY